Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

Recently Expanded Clinical Program Now Includes Solid and Hematological
Malignancies

ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq:
ENMD), a clinical-stage pharmaceutical company developing therapeutics for the
treatment of cancer today announced the presentation of clinical data for its
Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the American Society of
Clinical Oncology (ASCO) Annual Meeting being held this week in Orlando,
Florida. Data were presented in both oral discussion and poster sessions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076, a small molecule, oral kinase inhibitor that targets Aurora A and
other kinases critical to angiogenesis, cellular growth and proliferation, was
studied in patients with refractory solid tumors. Data from the 25 patients
who participated demonstrated that ENMD-2076 administered orally in daily
doses is associated with clinical benefit as determined by reductions in tumor
volume, reductions in tumor markers, and improvement in cancer-related
symptoms. These benefits were demonstrated in patients with a variety of tumor
types including melanoma, renal cell, ovarian and colorectal cancer. ENMD-2076
was well-tolerated when administered daily.

In addition, plasma soluble KDR (VEGFR2), a marker of effect against the VEGF
receptor, was reduced in all patients when compared to baseline. Side effects
included hypertension and low blood counts, consistent with the known targets
of ENMD-2076. Plasma concentrations at the higher dose levels evaluated were
within the range of where there was excellent antitumor activity in
preclinical models.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D.,
M.B.A., commented, "Plans are underway to expand this study and evaluate
additional patients with a variety of cancers as well as specifically those
with colorectal and ovarian cancers. These additional data will guide our
selection of the most promising solid tumor indications for further study in
Phase 2. The recent initiation of Phase 1 studies in multiple myeloma and
leukemia will allow us to extend the possible indications for ENMD-2076 into
hematological malignancies where preclinical data have been encouraging.
These data and the initiation of additional studies have added significant
value to the program and, in line with the Company's strategy to accelerate
the clinical development of ENMD-2076, partnering discussions continue."

To view a copy of the poster and slide presentations, visit Scientific
Presentations under the Therapeutic Pathways section of the Company's web site
at www.entremed.com.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a
unique kinase selectivity profile and multiple mechanisms of action.
Preclinical studies with ENMD-2076 demonstrated significant antitumor
activity, including tumor regression, in multiple solid and hematological
malignancies. ENMD-2076 has been shown to inhibit a distinct profile of
angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora
kinases are key regulators of mitosis (cell division), and are often
over-expressed in human cancers. ENMD-2076 also targets the Flt-3 and FGFR3,
kinases which have been shown to play important roles in the pathology of
hematological cancers.

About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to
developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for
the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in
advanced cancers and multiple myeloma. The Company's other therapeutic
candidates include MKC-1, an oral cell-cycle regulator with activity against
the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and
ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced
cancers. The Company also has an approved IND application for Panzem(R) in
rheumatoid arthritis. Additional information about EntreMed is available on
the Company's web site at www.entremed.com and in various filings with the
Securities and Exchange Commission.

Forward Looking Statements
This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance (including the
timing of royalty revenues and future R&D expenditures), strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed. Actual results could differ materially
from those currently anticipated due to a number of factors, including those
set forth in Securities and Exchange Commission filings under "Risk Factors,"
including risks relating to the need for additional capital and the
uncertainty of additional funding; variations in actual sales of Thalomid(R),
risks associated with the Company's product candidates; the early-stage
products under development; results in preclinical models are not necessarily
indicative of clinical results, uncertainties relating to preclinical and
clinical trials; success in the clinical development of any products;
dependence on third parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed products (such as
marketing, safety, regulatory, patent, product liability, supply, competition
and other risks).

CONTACT:
Ginny Dunn
Associate Director, Corporate Communications & Investor Relations
EntreMed, Inc.
240.864.2643

SOURCE EntreMed, Inc.

Ginny Dunn, Associate Director, Corporate Communications & Investor Relations
of EntreMed, Inc., +1-240-864-2643